8-K: Avalo Therapeutics Doses First Patient in Phase 2 Trial for Hidradenitis Suppurativa Treatment

Avalo Therapeutics has initiated its Phase 2 LOTUS trial, dosing the first patient with AVTX-009 for the treatment of hidradenitis suppurativa.

Summary

• Avalo Therapeutics has begun its Phase 2 LOTUS trial for AVTX-009, a monoclonal antibody targeting interleukin-1 (IL-1), to treat hidradenitis suppurativa (HS).
• The trial will enroll approximately 180 adults with moderate to severe HS and will compare two dose regimens of AVTX-009 against a placebo.
• The primary goal of the trial is to measure the proportion of patients achieving a 75% reduction in HS symptoms (HiSCR75) after 16 weeks.
• Secondary goals include measuring HiSCR50 and HiSCR90, changes in disease severity scores, and reductions in pain.
• Topline data from the trial is expected in 2026.
• AVTX-009 is a highly potent inhibitor of IL-1, which is a key driver of inflammation in HS.
• The company believes AVTX-009 has the potential to be a best-in-class treatment for HS, a market expected to reach $10 billion.
• Avalo has an expected cash runway into 2027.

Sentiment

Score: 8

Explanation: The document is positive, highlighting the initiation of a key clinical trial and the potential of the drug. The company has a strong management team and a clear path forward. The market opportunity is large and the drug has a strong profile.

Positives

• AVTX-009 has a clinically validated mechanism of action targeting IL-1.
• The drug has shown high potency and a favorable half-life, potentially allowing for less frequent dosing.
• AVTX-009 has demonstrated a favorable safety profile in previous clinical trials.
• The company has a strong management team with extensive experience in the pharmaceutical and biotech industries.
• The company has an expected cash runway into 2027.
• The company has a strong pharmacokinetic profile with high bioavailability and a long half-life.

Negatives

• The company is still in the clinical trial phase, and there is no guarantee of success.
• The company is reliant on the successful completion of the Phase 2 trial.
• The company is subject to general economic and market risks.

Risks

• The success of the Phase 2 trial is not guaranteed, and results may not be positive.
• The company is subject to regulatory risks and may not receive approval for AVTX-009.
• The company is reliant on key personnel, and their departure could impact operations.
• The company is subject to general economic and market risks, including those caused by the war in Ukraine and the Middle East.
• There are risks associated with the integration of AVTX-009 into the company's operations.

Future Outlook

The company anticipates topline data from the Phase 2 LOTUS trial in 2026 and plans to initiate a Phase 2b/3 trial in 2027 or later. They also plan to explore additional indications for AVTX-009, including inflammatory bowel disease.

Management Comments

• Dr. Garry Neil, Chief Executive Officer and Chairman of the Board, stated that they believe AVTX-009's high potency could make it a best-in-class treatment for hidradenitis suppurativa.
• Management is excited to have the Phase 2 trial underway.

Industry Context

The announcement is significant as it marks the progression of a potential new treatment for hidradenitis suppurativa, a chronic inflammatory skin condition with limited treatment options. The company is targeting a market that is expected to grow substantially, with a projected value of $10 billion.

Comparison to Industry Standards

• AVTX-009 is compared to canakinumab (ILARIS), an existing IL-1 inhibitor, and is shown to have superior potency in vitro with a KD of <3 pM compared to 60 pM for canakinumab.
• The company references other treatments for HS, such as anti-TNF drugs (Humira), anti-IL-17 drugs (Cosentyx, Bimzelx), and JAK1 inhibitors (Rinvoq), highlighting the potential for AVTX-009 to offer a more targeted approach with fewer side effects.
• The company's Phase 2 trial design is similar to other trials in HS, using HiSCR75 as the primary endpoint, which is a standard measure of efficacy in this disease.
• The company is also exploring the potential of AVTX-009 in inflammatory bowel disease (IBD), similar to AbbVie's exploration of lutikizumab, a dual variable domain IL-1/1 antagonist.

Stakeholder Impact

• Shareholders may see a positive impact if the Phase 2 trial is successful.
• Employees may benefit from the company's growth and success.
• Patients with hidradenitis suppurativa may have a new treatment option if AVTX-009 is approved.
• The company's success could lead to increased revenue for suppliers and partners.

Next Steps

• The company will continue to enroll patients in the Phase 2 LOTUS trial.
• The company will monitor the safety and efficacy of AVTX-009 in the trial.
• The company will release topline data from the trial in 2026.
• The company plans to initiate a Phase 2b/3 trial in 2027 or later.
• The company will explore additional indications for AVTX-009, including inflammatory bowel disease.

Key Dates

Keywords

AVTX-009, hidradenitis suppurativa, IL-1, monoclonal antibody, Phase 2 trial, LOTUS trial, clinical trial, inflammatory disease, biotechnology, dermatology